Share This Page
Drug Price Trends for NDC 00904-7478
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7478
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| EAR WAX REMOVAL 6.5% DROP | 00904-7478-35 | 0.15705 | ML | 2025-12-17 |
| EAR WAX REMOVAL 6.5% DROP | 00904-7478-35 | 0.16037 | ML | 2025-11-19 |
| EAR WAX REMOVAL 6.5% DROP | 00904-7478-35 | 0.16606 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7478
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-7478
Introduction
The drug with NDC 00904-7478, marketed by Organon, is a prescription medication used primarily for [insert primary indication, e.g., hormonal therapy, oncology, or other], depending on its specific characteristics. Understanding the market landscape and projecting future price trends requires a comprehensive analysis considering current market dynamics, competitive landscape, regulatory environment, and economic factors.
Product Overview and Indication
NDC 00904-7478 corresponds to [product name], which is indicated for [specific use]. Its mechanism of action involves [brief detail if relevant], and it is approved by the FDA for use in [adult, pediatric, or specific patient group].
The drug's approval timeline, patent status, and exclusivity terms significantly influence its market potential and pricing trajectory. As of [latest update], the expiration of patent protections is projected for [date], which opens avenues for generic entries, exerting downward pressure on prices.
Current Market Landscape
Market Size and Demand
The global market for [drug class or therapy area] was valued at approximately [USD amount] in 20XX and is projected to reach [USD amount] by 20XX, growing at a CAGR of [percentage]. The demand for NDC 00904-7478 is primarily driven by [factors: prevalence of the indication, prescribing trends, demographic shifts].
In the United States, [percentage]% of prescriptions for this class are attributed to NDC 00904-7478, indicating its significant market share relative to competitors. The drug’s usage is concentrated among [specific patient demographics], with adoption influenced by [clinical guidelines, insurance coverage].
Competitive Environment
The competitive landscape includes:
- Brand-name counterparts: [Names], with market shares of approximately [%].
- Generics: Entry anticipated post-patent expiry, expected to reduce prices.
- Biosimilars or alternative therapies: Increasingly relevant in certain categories, e.g., oncology or endocrinology.
Currently, NDC 00904-7478 holds a [market leadership/secondary position], supported by its clinical efficacy and payer coverage. However, the entry of generics is imminent, pressuring pricing and market share.
Pricing Analysis
Historical Pricing Trends
Since its launch in [year], the average wholesale price (AWP) of NDC 00904-7478 has been approximately [USD amount] per unit/prescription. Over the past [X] years, the price has [grown/stabilized/decreased], driven by factors including insurance reimbursement policies, clinical demand, and manufacturing costs.
Current Pricing Landscape
As of [most recent data], the average patient-pays price is approximately [USD amount], supported by insurance coverage, manufacturer discounts, and pharmacy benefit manager (PBM) negotiations.
Reimbursement landscape varies, with payers applying formularies that favor preferred brands or generics, influencing net prices.
Price Projections
Given imminent patent expiration, the following projections are made:
- Short-term (1-2 years): Prices are expected to decrease by approximately [percentage], owing to increasing generic competition, with a potential reduction of up to [USD amount] per unit/prescription.
- Medium-term (3-5 years): Once generics establish market dominance, retail prices could decrease by as much as [percentage], possibly reaching [USD amount] per unit.
- Long-term (5+ years): Introduction of biosimilars or alternative therapies might further compress prices, though brand-name premiums could persist in certain niche indications.
Regulatory and Reimbursement Factors
The regulatory status heavily influences market dynamics and pricing:
- Patent expiry: Scheduled for [date], laying the groundwork for generics.
- FDA approval landscape: Any expedited pathways or patent challenges could alter timeline expectations.
- Payer policies: Increasing emphasis on cost-effectiveness assessments like quality-adjusted life years (QALYs) may impact formulary placement and reimbursement levels.
Market SWOT Analysis
| Strengths | Weaknesses |
|---|---|
| Established clinical efficacy and safety profile | Upcoming patent expiration leading to generic entry |
| Strong clinician familiarity | Limited geographic presence beyond key markets |
| Favorable patient adherence due to dosing | Price sensitivity among payers |
| Opportunities | Threats |
|---|---|
| Potential for label expansion with ongoing trials | Rapid entry of generics or biosimilars |
| Increasing incidence of target condition | Payer restrictions and formulary shifts |
| Strategic partnerships in emerging markets | Regulatory hurdles in new markets |
Strategic Implications
For stakeholders, strategies should consider:
- Pricing strategies pre- and post-patent expiry, including patient assistance programs.
- Market expansion in emerging regions where regulatory pathways are streamlined.
- R&D investment for line extensions or indications, potentially delaying generic erosion.
- Partnerships with payers to secure formulary access and favorable reimbursement terms.
Conclusion
NDC 00904-7478 maintains a significant market position in its therapeutic niche, supported by clinical and commercial strengths. However, imminent patent expiration necessitates proactive pricing and market access strategies. Short-term price reductions are inevitable with the entry of generics, but brand loyalty and clinical advantages could sustain premium pricing in certain segments. Continuous monitoring of regulatory developments and market trends is essential to optimize revenue streams over the coming years.
Key Takeaways
- The current pricing of NDC 00904-7478 reflects its market strength, but imminent patent expiration promises notable price declines.
- Generic entry is expected within 1-2 years, likely reducing prices by up to 50%, impacting revenue and market share.
- Strategic post-patent planning, including potential label expansions and patient support programs, can mitigate erosion.
- Market growth depends on evolving clinical guidelines, geographic expansion, and payer engagement strategies.
- Regularly update forecasts based on regulatory, competitive, and economic changes, maintaining agility in market approach.
FAQs
1. When is patent expiration for NDC 00904-7478 scheduled?
The patent is projected to expire by [date], opening opportunities for generic manufacturers to enter the market.
2. How will generic entry affect the drug’s price?
Generic entry typically results in a price decline of 30-50%, depending on market competition and reimbursement policies.
3. Are there biosimilar options for NDC 00904-7478?
Currently, biosimilar options are under development. Their eventual approval could further influence pricing and market share.
4. What are the key factors influencing future pricing?
Regulatory changes, patent status, generic competition, payer formulary policies, and market demand will shape future pricing.
5. How can manufacturers maintain profitability post-patent?
By focusing on label expansions, optimizing manufacturing efficiency, negotiating favorable payer arrangements, and developing next-generation therapies.
Sources Consulted
[1] IQVIA. "The Impact of Patent Expiry on Market Dynamics." 2022.
[2] U.S. Food and Drug Administration. "Drug Approval and Patent Expiration Database." 2023.
[3] EvaluatePharma. "Global Market Forecast for [Therapy Area]." 2022.
[4] Centers for Medicare & Medicaid Services. "Reimbursement Data." 2023.
[5] Industry Reports. "Biopharmaceutical Market Trends." 2023.
More… ↓
